Please login to the form below

Not currently logged in

Ardea CEO and COO join board of AP Pharma

Appointments of Barry Quart and Stephen Davis come as AstraZeneca completes purchase of Ardea

Barry Quart - AP Pharma and Ardea BiosciencesThe CEO and chief operating officer of Ardea Biosciences, which was recently acquired by AstraZeneca, have joined the board of directors at specialty pharma company AP Pharma.

The addition of Ardea's president, CEO and director Dr Barry Quart (pictured) and executive VP and chief operating officer Stephen Davis take the total number of AP Pharma board members to six, bringing experience to the company as it prepares to seek approval for cancer symptom drug APF530.

"Gaining access to Barry's significant drug development and regulatory experience will be invaluable as we seek FDA approval for our lead product candidate, APF530, for the prevention of chemotherapy-induced nausea and vomiting,” said AP Pharma's president and CEO John Whelan.

“Furthermore, Steve's proven business acumen will be instrumental as we prepare for the potential commercialisation of APF530 and look to maximise the value of both this asset and our Biochronomer drug delivery platform."

Dr Quart has been in his position at Ardea, which was purchased by AZ for $1.26bn, since it was founded in 2006. Previously he was with Pfizer, serving as senior VP global R&D and director of the La Jolia Laboratories.

Prior to Pfizer's acquisition of Warner-Lambert, Dr Quart was president of R&D at Agouron Pharmaceuticals, a division of Warner-Lambert.

Davis joined Ardea in 2010 after leaving his position as CEO and director of Neurogen Corporation. He held several other roles at Neurogen before becoming CEO, including chief operating officer.

25th June 2012


Featured jobs

Subscribe to our email news alerts


Add my company
Real Science Communications

Real Science Communications is a scientific centre of excellence, infusing credibility and scientific rigour into the conversations around health and...

Latest intelligence

Digital health
The untapped potential to transform healthcare...
When is it time to rebrand?
The Biosimilar Challenge